Clinical trial
A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder…
NCT00224029 · Watson Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00224029 |
|---|---|
| Title | A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition |
| Official title | A Multi-center, Open-label, Dose-titration Pilot Study Evaluating the Efficacy and Safety of Oxybutynin Transdermal Systems in Patients With Neurogenic Bladder Resulting From Spinal Cord Injury |
| Lead sponsor | Watson Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Detrusor Hyperreflexia |
| Intervention type | Drug |
| Interventions | Oxybutynin transdermal system |
| Enrollment | 24 |
| Start date | Dec 1, 2004 |
| Primary completion | Dec 1, 2005 |
| Completion | May 1, 2008 |
| First posted | Sep 22, 2005 |
| Last update posted | Apr 30, 2010 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: